Literature DB >> 15649310

IMPs, VIMs and SPMs: the diversity of metallo-beta-lactamases produced by carbapenem-resistant Pseudomonas aeruginosa in a Brazilian hospital.

H S Sader1, A O Reis, S Silbert, A C Gales.   

Abstract

Pseudomonas aeruginosa isolates (n=183), collected from bacteraemic patients hospitalised in Sao Paulo Hospital (Brazil) during 2000-2001, were screened for susceptibility to antimicrobial agents. The polymyxins were the most active compounds (100% susceptibility), followed by amikacin and cefepime (59.0%), meropenem (57.4%), and imipenem and gentamicin (55.2%). Imipenem-resistant isolates were ribotyped and screened for production of metallo-beta-lactamases (MBLs) by PCR with primers for bla(IMP), bla(VIM) and bla(SPM). MBL production was detected in 36 isolates (19.7% of the entire collection; 43.9% of the imipenem-resistant isolates) and the MBLs included SPM-1-like (55.6%), VIM-2-like (30.6%) and IMP-1-like (8.3%) enzymes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15649310     DOI: 10.1111/j.1469-0691.2004.01031.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  17 in total

1.  Bloodstream infections with metallo-beta-lactamase-producing Pseudomonas aeruginosa: epidemiology, microbiology, and clinical outcomes.

Authors:  Alexandre R Marra; Carlos Alberto P Pereira; Ana Cristina Gales; Liana C Menezes; Ruy Guilherme R Cal; José Marconi A de Souza; Michael B Edmond; Cynthia Faro; Sérgio B Wey
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

2.  High prevalence of metallo-beta-lactamase and 16S rRNA methylase coproduction among imipenem-resistant Pseudomonas aeruginosa isolates in Brazil.

Authors:  Yohei Doi; Angela C R Ghilardi; Jennifer Adams; Doroti de Oliveira Garcia; David L Paterson
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

Review 3.  Carbapenemases: the versatile beta-lactamases.

Authors:  Anne Marie Queenan; Karen Bush
Journal:  Clin Microbiol Rev       Date:  2007-07       Impact factor: 26.132

4.  Detection of Pseudomonas aeruginosa producing metallo-beta-lactamases in a large centralized laboratory.

Authors:  Johann D D Pitout; Daniel B Gregson; Laurent Poirel; Jo-Ann McClure; Phillip Le; Deirdre L Church
Journal:  J Clin Microbiol       Date:  2005-07       Impact factor: 5.948

5.  High prevalence of metallo-beta-lactamase-mediated resistance challenging antimicrobial therapy against Pseudomonas aeruginosa in a Brazilian teaching hospital.

Authors:  A P Zavascki; L Z Goldani; A L S Gonçalves; A F Martins; A L Barth
Journal:  Epidemiol Infect       Date:  2006-07-07       Impact factor: 2.451

6.  Diversity of beta-lactamases produced by ceftazidime-resistant Pseudomonas aeruginosa isolates causing bloodstream infections in Brazil.

Authors:  Renata C Picão; Laurent Poirel; Ana C Gales; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2009-07-13       Impact factor: 5.191

7.  Metallo-beta-lactamases among imipenem-resistant Pseudomonas aeruginosa in a Brazilian university hospital.

Authors:  Maria Renata Gomes Franco; Hélio Hehl Caiaffa-Filho; Marcelo Nascimento Burattini; Flávia Rossi
Journal:  Clinics (Sao Paulo)       Date:  2010       Impact factor: 2.365

8.  Green synthesis of Al2O3 nanoparticles and their bactericidal potential against clinical isolates of multi-drug resistant Pseudomonas aeruginosa.

Authors:  Mohammad A Ansari; Haris M Khan; Mohammad A Alzohairy; Mohammad Jalal; Syed G Ali; Ruchita Pal; Javed Musarrat
Journal:  World J Microbiol Biotechnol       Date:  2014-10-11       Impact factor: 3.312

9.  Pseudomonas aeruginosa: resistance to the max.

Authors:  Keith Poole
Journal:  Front Microbiol       Date:  2011-04-05       Impact factor: 5.640

10.  Detection of P. aeruginosa harboring bla CTX-M-2, bla GES-1 and bla GES-5, bla IMP-1 and bla SPM-1 causing infections in Brazilian tertiary-care hospital.

Authors:  Milena Polotto; Tiago Casella; Maria Gabriela de Lucca Oliveira; Fernando G Rúbio; Mauricio L Nogueira; Margarete Tg de Almeida; Mara Cl Nogueira
Journal:  BMC Infect Dis       Date:  2012-08-03       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.